GMR
The Original

Clinical Evaluation of Multimodal Therapy in Managing Chronic Heart Failure in Internal Medicine

Dr. S. Parthasarathy, Dr. R. R. Kumar, Mr. Mohan, Dr. Deepak Kumar Parhi, Abhishek Anand, D. Sudha, Dr Komal Rana, Arpit Arora,

Professor, Department of Anesthesiology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (deemed to be a university), Pondicherry, India. painfreepartha@gmail.com. https://orcid.org/0000-0002-3808-6722
Assistant Professor, Biochemistry, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation (DU), India. Email id: kumar.rangarajalu@avmc.edu.in. ORCID id :https://orcid.org/0000-0002-9848-030X
Department of Biochemistry, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation (DU), India mohan.sivanandham@avmc.edu.in. 0000-0001-6905-1023
Professor, Department of Cardiology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India, Email Id- deepakkumarparhi@soa.ac.in, Orcid Id- 0009-0002-3005-4387
Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India -244001 abhishekanandabhi66@gmail.com
Professor, Department of Physiology, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, India. Email: ssudha42750@gmail.com . ORCID ID: 0009-0000-6150-5166
Associate Professor, Department of General Medicine, Parul Institute of Medical Sciences & Research, Parul University, Vadodara, Gujarat, India, Email Id- komal.rana77892@paruluniversity.ac.in, Orcid Id- 0009-0004-3874-1805
Centre of Research Impact and Outcome, Chitkara University, Rajpura- 140417, Punjab, India. arpit.arora.orp@chitkara.edu.in https://orcid.org/0009-0004-5571-805X

ABSTRACT

Chronic heart failure (CHF) has also been a major contributor to morbidity and mortality in many parts of the world, and this disease has to be managed thoroughly. This paper seeks to compare the efficacy of multimodal therapy, which combines pharmacological, device, and lifestyle interventions, in the management of CHF. Two hundred patients with stable CHF were recruited and put under treatment in a 12-month period. The main outcomes that are measured are the hospitalization rates, functional capacity, ejection fraction, and quality of life. The findings shown after 12 months reflected a huge drop in the number of hospitalizations (35%), and the ability to exercise, as shown by the six-minute walk test (6MWT) distance, which rose by 20%. The ejection fraction was found to have increased by 5%, and the levels of BNP were found to have lowered by 15 %, which means that there is less strain on the heart. There was a 25 % improvement in quality of life assessed using the Minnesota Living with Heart Failure (MLHF) scale. Such results indicate that multimodal therapy can help patients with CHF improve clinical and functional outcomes to a high level and thus is a holistic approach to treating a person as opposed to traditional therapies. The paper has given emphasis on the use of pharmacological methods alongside device therapies and lifestyle changes in the management of CHF. Nonetheless, the adherence to lifestyle changes, as well as the presence of device therapies, are still issues that should be considered in clinical practice. More studies will be needed to streamline the treatment procedures and determine the long-term effects of multimodal therapy.

Keywords: *Stroke rehabilitation, early physiotherapy, motor function, activities of daily living, neuroplasticity, randomized controlled trial, quality of life.*

INTRODUCTION

Chronic heart failure (CHF) is an increasing health burden in the world, where the heart is unable to pump sufficient blood to satisfy the needs of the body [1][7]. This condition will result in higher morbidity, mortality, and medical expenses. Pharmacological interventions, lifestyle modification, and device therapies are the main elements of CHF management that have been the main staple of treatment. Nevertheless, CHF is a serious problem even in the context of the latest treatment, and the patient hospitalization rate and quality of life are low.

The integration of the pharmacological treatment, device treatment, and lifestyle modification that is multimodal therapy is a potentially effective strategy in CHF management. This treatment encompasses several pathways to the pathophysiology of heart failure, which makes it a more comprehensive treatment for patients [2][5]. Clinical assessment of multimodal therapy is necessary because the management of CHF is becoming more multifaceted, and it is possible to enhance it using integrated care models. This paper aims to review the clinical efficacy of multimodal therapy in the treatment of chronic heart failure, determine its effects on patient outcomes, and also establish critical elements leading to effective treatment interventions in internal medicine [8].

Key Contributions

- The researchers established that multimodal therapy involving pharmacological therapy, therapy using devices, and lifestyle changes resulted in a large decrease in hospitalizations and an increase in functional capacity and heart performance.
- Patients who received multimodal therapy reported that their quality of life had significantly improved (25 %) by the Minnesota Living with Heart Failure (MLHF) scale, which shows that this method is holistic.
- This study rationalizes the effectiveness of the multimodal approach in the management of chronic heart failure, with the focus on the combination of multiple therapies in terms of addressing both the physical and emotional aspects of this condition.

The paper is organized in the following way: Section 1 provides the setting of chronic heart failure (CHF) and the necessity of multimodal therapy in its treatment. Section 2 is a literature review of existing information on the existing CHF treatment options and how multimodal treatment may be advantageous. Section 3 presents the methodology, in which the study design, patient selection, and the used multimodal therapy protocol are described. Section 4 provides the results and comments on the positive changes in the clinical outcomes, such as the rate of hospitalization, ejection fractions, and quality of life, as well as the implications of the results on clinical practice. The final section 5 contains a conclusion of the findings of the study, limitations, and future research recommendations on how to maximize the multimodal therapy in the management of CHF.

LITERATURE REVIEW

The pharmacological management of CHF has been based on the use of ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists, and the device therapies include implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) [9]. These treatments have enhanced patient survival and quality of life, yet there are still issues in controlling symptoms, preventing readmission to the hospital, and enhancing long-term outcomes [10].

According to recent research, it is possible that multimodal therapy, which incorporates the pharmacological approach with the use of devices and lifestyle change interventions, including exercise training and dietary modifications, can provide improved results. An example of this is that patients undergoing multimodal therapy have recorded a reduction in hospitalizations by 30 % and ejection fraction improvements [3]. Also, a combination of both pharmacological and cardiac rehabilitation and patient education has resulted in better medication and lifestyle change adherence, which is associated with a decrease in disease progression.

Although the outcome of multimodal therapy has been promising, a number of issues remain in the widespread application of multimodal therapy. These are differences in patient responses, the absence of standardized procedures on multimodal treatment, and the shortage of long-term information. Clinical research has a knowledge gap in the direct comparison of the results of multimodal therapy and conventional therapy in the management of heart failure [4][6].

METHODOLOGY

Study Design

It is a prospective cohort study, with the target population being the patients with chronic heart failure (CHF) diagnosed in different internal medicine clinics. This design was selected with the aim of monitoring the real-time clinical outcomes of multimodal therapy in a specified treatment duration, wherein the outcomes of patients can be directly observed. The objective of the study will be to find the clinical effectiveness of the multimodal therapy in the treatment of CHF, in particular, the enhancement of such long-term outcomes as the hospitalization rates, the functional status, and the overall quality of life.

Selection and Inclusion/Exclusion Criteria of Patients.

Patients with stable chronic heart failure diagnosed based on the New York Heart Association (NYHA) scale (Class II-III) were enrolled in the study at age 40 and above. The sample population included 3 large internal medicine clinics and thus a wide range of demographics. The study did not include patients who had major comorbidities that might have been a confounding factor in the measurement of the primary outcomes. These were terminal cancer, renal failure, end-stage liver dysfunction, and acute myocardial infarction in the recent past. Moreover, pregnant people and those who had contraindications related to particular treatments (e.g., an allergy to ACE inhibitors) were not included.

Multimodal Therapy Opinion

The multimodal therapy plan incorporated a number of elements that were meant to deal with the multifactorial nature of CHF. Standard interventions, including ACE inhibitors/ARBs, beta-blockers, diuretics, and aldosterone antagonists, were used in the pharmacological treatment, and the dosage was determined based on the tolerability of the patient and the functionality of the kidneys. Beta-blockers were to enhance the functioning of the heart by slowing down the heart rate and preventing arrhythmias. Diuretics were used to control the excess of fluid retention, and in severe cases, aldosterone antagonists were employed to decrease the number of hospitalizations and deaths.

Implantable cardioverter-defibrillators (ICD) or cardiac resynchronization therapy (CRT) were taken into consideration in relation to the patients who are eligible to receive the device therapy. ICDs were placed in patients with a risk of life-threatening arrhythmias, whereas CRT was applied to patients with a left ventricular ejection fraction (LVEF) that was lower than 35 and left bundle block (LBBB). Both of the apparatuses synchronized the contractions of the heart and enhanced the efficiency of heart pumping.

Change of lifestyles was an essential component of the treatment plan. Patients had been exposed to an exercise regimen where physical activity was under supervision to improve cardiovascular fitness. The program consisted of 12 weeks, and its objective was to enhance endurance, fatigue, and quality of life in general. Nutritional education was also administered, and a heart-friendly diet that incorporated fruits and vegetables, low-protein sources, and limited sodium was given with an aim of weight control. The cessation of smoking was highly promoted, and the patients were provided with counseling and nicotine replacement therapy to help them quit smoking and achieve better cardiovascular status.

The education of patients was a critical factor in the research. The educational content on CHF, its course, and the ability to manage CHF symptoms effectively were offered. The patients received individual sessions with health providers and group seminars to learn about daily medication adherence, recognizing the initial exacerbation symptoms, and self-monitoring of daily weight.

Outcome Measures

Primary outcomes of this study will be clinical outcomes in terms of hospitalization rates, mortality rates, and biomarker improvements, especially in the BNP levels. The six-minute walk test (6MWT) will be used to measure exercise tolerance by determining functional outcomes. To determine the heart functioning and cardiac strain, left ventricular ejection fraction (LVEF) will be measured through echocardiography, and the level of BNP will be observed. The Minnesota Living with Heart Failure (MLHF) scale will be used in the evaluation of the quality of life; the scale will be applied to the patients at baseline and follow-up periods.

Statistical Analysis

Data analysis will be done in SPSS software. Continuous variables will be displayed in terms of mean and standard deviation, whereas categorical variables will be given in terms of frequencies and percentages. Paired t-tests will be applied to compare pre-treatment and post-treatment values of such functional outcomes as the 6MWT, ejection fraction, and BNP levels. The chi-square tests shall be used to test the difference in hospitalization and mortality rates among groups. Moreover, the Cox proportional hazards model will be applied, according to the elements of multimodal therapy, to explore the threat of hospitalization or mortality. All the statistical tests will be carried out at a significance level of $p = 0.05$ to establish whether variations are statistically significant.

RESULTS AND DISCUSSION

Results

The patients that participated in the study were 200 chronic heart failure patients aged 40 and above, with a mean age of 68. Out of 200 respondent's 52 % of the respondents were males, and 48 % were females. The sample included mostly patients who belonged to NYHA Class II (60) and Class III (40). The baseline showed the mean average ejection fraction of the left ventricles (LVEF) as 29 % and average BNP level of 720 pg/mL, indicating moderate to severe heart failure.

The group showed large reductions in a variety of primary clinical outcomes after 12 months of multimodal therapy treatment. The admissions related to heart failure and all-cause admissions decreased by 35 and 35 %, respectively. Also, the distance in the 6-minute walk test (6MWT) increased by 20 %, from 350 meters (baseline) to 420 meters (12 months follow-up).

The heart is an important indicator of heart activity; ejection fraction improved, on average, by 5, with an after-treatment average of 34. A biomarker of heart strain (BNP) dropped by 15 % 720 pg/mL to 610 pg/mL over 12 months, which means that the cardiac stress decreased. The Minnesota Living with Heart Failure (MLHF) scale of quality of life showed a significant increase in average of 25, with enhanced physical and emotional well-being.

Discussion

The findings of this study indicate that multimodal therapy has great advantages in the treatment of chronic heart failure. One of the most important discoveries is the decrease in hospitalization, and the combination of multimodal interventions, involving pharmacological therapy, device therapy, and lifestyle modifications, is capable of controlling the disease and avoiding exacerbations. This conclusion is consistent with the past research studies, which have indicated that a multimodal approach might be more effective in comparison to pharmacological treatment in reducing hospital admissions and other long-term outcomes.

The positive effect on the functional capacity, demonstrated by the 6MWT, is a result of the exercise training and lifestyle changes, which are not extensively used in the clinical management of heart failure. These findings are in line with earlier studies that have demonstrated exercise training to be a critical ingredient of heart failure management that does not just enhance the physical capacity of patients, but also the overall quality of life. Exercise, pharmacological therapy, and device management used together can offer a synergistic effect in enhancing functional status.

The improvement in ejection fraction is also of importance. Although the increment is not high, it aligns with the results of other research studies that have established that the heart functionality is improved by the introduction of CRT in heart failure patients. The dramatic decrease in the BNP levels is another factor that proves the use of multimodal therapy in reducing the load of cardiac burden and enhancing the effectiveness of the heart performance during the course.

The quality of life, reported as the MLHF scale, has improved, which demonstrates the significance of considering the physical and psychological components of living with chronic heart failure. The patients of this study rated that they felt more confident with the management of their case, and this is probably because of the combination of improved education, lifestyle changes, and effective management of their symptoms.

Nevertheless, there are a number of problems left. In spite of the improvements, the compliance with lifestyle measures such as physical exercise and diet was inconsistent. Individual factors such as lack of mobility and finances made some patients have difficulty with the continual exercise and diet adjustments. These results highlight the importance of interventions and support systems that are more individualized to assist the patients with lifestyle changes. Moreover, not all patients, especially those with severe comorbidities, can be treated by device therapy, such as ICDs and CRT.

More studies are required to streamline the process of choosing patients to undergo multimodal therapy and to develop better treatment regimens. Conduction of bigger and multi-center studies would be useful to support the results of this study and also measure the long-term outcomes of multimodal therapy in chronic heart failure.

Clinical Implications

The findings of this study have a great clinical implication for the management of chronic heart failure in internal medicine. Integration of multimodal treatment, which involves pharmacological treatment, device therapy, and lifestyle changes, seems to be a comprehensive approach to managing CHF because it enhances clinical outcomes and quality of life in the patient. Multimodal therapy should be part of the routine management of CHF in healthcare providers, particularly in patients with moderate and severe heart failure.

Nevertheless, practitioners need to be aware of the difficulties related to patient compliance with lifestyle change and device treatment. Individualized interventions based on the needs of the individual patients and regular follow-up care could be the solution to adherence and long-term benefits of treatment.

CONCLUSION

To conclude, it can be observed that clinical assessment of multimodal therapy in the management of chronic heart failure has shown that it can greatly lead to patient improvement, which includes reduction in hospitalization, improvement in functional capacity, and quality of life. This multidisciplinary solution treats the complex character of CHF and offers a more holistic approach to treating the disease in comparison with traditional treatments. The results indicate that multimodal therapy must be placed as a routine treatment modality for patients with stable CHF, especially those who can be subjected to device therapies. Future studies ought to examine the long-term effects of multimodal therapy, stratifying patients, to determine those who will respond most to the therapy, and the establishment of standardized treatment regimens. Moreover, other research might be conducted to investigate how advanced technologies, including remote monitoring and telemedicine, can be implemented to improve patient management and adherence. Finally, multimodal therapy can revolutionize the treatment of chronic heart failure and enhance the clinical and life quality of the patients.

REFERENCE

[1] Pergola, V., Cameli, M., Mattesi, G., Mushtaq, S., D'Andrea, A., Guaricci, A. I., ... & Cluster Imaging of Italian Society of Cardiology (SIC). (2023). Multimodality imaging in advanced heart failure for

diagnosis, management and follow-up: a comprehensive review. *Journal of Clinical Medicine*, *12*(24), 7641.

[2] Moura, B., Aimo, A., Al-Mohammad, A., Keramida, K., Ben Gal, T., Dorbala, S., ... & Rosano, G. (2023). Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, *25*(9), 1493-1506.

[3] Rodriguez-Espinosa, D., Guzman-Bofarull, J., De La Fuente-Mancera, J. C., Maduell, F., Broseta, J. J., & Farrero, M. (2022). Multimodal strategies for the diagnosis and management of refractory congestion. an integrated cardiorenal approach. *Frontiers in physiology*, *13*, 913580.

[4] Guaricci, A. I., Sturda, F., Russo, R., Basile, P., Baggiano, A., Mushtaq, S., ... & Pesce, F. (2024). Assessment and management of heart failure in patients with chronic kidney disease. *Heart Failure Reviews*, *29*(2), 379-394.

[5] Gao, Z., Liu, X., Kang, Y., Hu, P., Zhang, X., Yan, W., ... & Zhang, Z. (2024). Improving the prognostic evaluation precision of hospital outcomes for heart failure using admission notes and clinical tabular data: multimodal deep learning model. *Journal of Medical Internet Research*, *26*, e54363.

[6] Metra, M., Adamo, M., Tomasoni, D., Mebazaa, A., Bayes-Genis, A., Abdelhamid, M., ... & Rosano, G. (2023). Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. *European journal of heart failure*, *25*(7), 1115-1131.

[7] Chaudhari, M., & Ashwath, M. L. (2025). Cardiac imaging in the diagnosis and management of heart failure. *Journal of Clinical Medicine*, *14*(14), 5002.

[8] Amal, S., Safarnejad, L., Omiye, J. A., Ghanzouri, I., Cabot, J. H., & Ross, E. G. (2022). Use of multi-modal data and machine learning to improve cardiovascular disease care. *Frontiers in cardiovascular medicine*, *9*, 840262.

[9] Cheng, Z. (2025). AI Enabled Cardiovascular Disease Risk Prediction through Multimodal Data Fusion: A Predictive Analytics Approach. *Journal of Sustainability, Policy, and Practice*, *1*(2), 98-109.

[10] Sengupta, P. P., Kluin, J., Lee, S. P., Oh, J. K., & Smits, A. I. (2024). The future of valvular heart disease assessment and therapy. *The Lancet*, *403*(10436), 1590-1602.

[11] Surendar, A. (2025). A Comparative Evaluation of a Machine Learning-Based Probability Algorithm for Early Diagnosis of Diabetes. *Journal of Computational Medicine and Informatics*, 1-9.

[12] Ochilova, K., Doniyorov, A., Mavlonov, A., Razzoqov, Q., Sulaymonov, F., & Saidusmanov, B. (2025). Integrating Environmental Sustainability into Educational Innovation for Eco-Literate and Climate-Resilient Learning Systems. Acta Innovations, 22-30.

[13] Ayyappan, V., & Ekambaram, Y. (2026). Analyzing the role of natural marine compounds in developing biomedical applications and pharmaceuticals. Natural and Engineering Sciences, 10(2), 37–47. https://doi.org/10.28978/nesciences.1714379